ArticleBMJ open2025

Multicentre open-label randomised controlled trial comparing the efficacy and safety of colistin-based combination therapy with the best available therapy for treating hospital-acquired pneumonia or bloodstream infections caused by carbapenem-resistant

Xiangquan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.